ABBV250103P152500
- 0.01
- 0.000.00%
AbbVie Newsroom
AbbVie Cuts 2024 Profit Forecast on Acquisition Expenses
Market Climbed Monday Just Past Santa Rally High Water Mark | Wall Street Today
AbbVie Announced Q4 2024 Earnings To Include $1.6B Acquired IPR&D Costs, Impacting EPS By $0.88; Final Results Pending; Q4 Adj EPS $2.06-$2.10; FY24 Adj EPS Guidance $10.02-$10.06
Express News | Abbvie Inc Q4 Shr View $2.98 -- LSEG IBES Data
Express News | Abbvie Inc - Q4 2024 Adj EPS Guidance Range $2.06 - $2.10
Express News | Abbvie Inc - Q4 2024 Earnings to Include $1.6 Billion Ipr&D Expense on Pre Tax Basis
CES Tech Conference Week Starts with Nvidia and Chips Climbing | Live Stock
Santa Clause Came and Went Without Bringing Gifts | Weekly Buzz
Friday? More Like Grinch Day | Wall Street Today
Santa Claus Came Without Rallying the Troops | Live Stock
AbbVie Hits 4-week High
Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Morgan Stanley Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $224
AbbVie to Host Full-Year and Fourth-Quarter 2024 Earnings Conference Call
Drug-Trial Results Could Shake Up Pharma Stocks in 2025. Watch Eli Lilly, Pfizer, and More. -- Barrons.com
AbbVie (ABBV) Gains As Market Dips: What You Should Know
AbbVie (ABBV) Upgraded to Buy: What Does It Mean for the Stock?
Brokers Suggest Investing in AbbVie (ABBV): Read This Before Placing a Bet
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It